Data from several RCTs have shown that [sodium-glucose cotransporter-2 inhibitors (SGLT-2i)] may have promising effects on fibrosis or steatosis, based on biological mechanisms of glucagon signaling pathways or insulin use reduction, Sungho Bea, PharmD, PhD, a postdoctoral fellow in the division of pharmacoepidemiology and pharmacoecomonics at Brigham and Womens Hospital and Harvard Medical School, and colleagues wrote in Gut
All records were exported from each database, de-duplicated in EndNote 21, and then transferred to Rayyan (Qatar Computing Research Institute) for screening [9]
But just incredible service
This reduces the risk of hypoglycaemia compared to some other diabetes medicines, though the risk increases when used alongside insulin or sulfonylureas
N-acetylcysteine (NAC) was introduced in the 1960s as a mucolytic drug for chronic respiratory diseases